

Edgar Filing: JOHNSON & JOHNSON - Form 8-K

JOHNSON & JOHNSON  
Form 8-K  
March 01, 2004

SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8K

Current Report Pursuant to Section 13 or 15(d) of  
The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 1, 2004

JOHNSON & JOHNSON

(Exact name of registrant as specified in its charter)

|  |                            |                                    |
|--|----------------------------|------------------------------------|
| New Jersey<br>1024240  | 1-3215                     | 22-                                |
| (State or other<br>jurisdiction<br>No.)<br>of incorporation) | Commission<br>File Number) | (I.R.S. Employer<br>Identification |

One Johnson & Johnson Plaza, New Brunswick, New Jersey 08933  
(Address of principal executive offices) (zip code)

Registrant's telephone number including area code: (732) 524-0400  
Item 5. Other Events.

On February 27, 2004, Johnson & Johnson ("J&J") issued the  
attached  
press release announcing the strategic alliance with Guidant  
Corporation for the co-promotion of drug-eluting stents.

(c) Exhibit

| Exhibit No.   | Description of Exhibit                 |
|---------------|--|
| Exhibit 99.17 | Press Release dated February 27, 2004. |

SIGNATURE

Edgar Filing: JOHNSON & JOHNSON - Form 8-K

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

JOHNSON & JOHNSON

Date: March 1, 2004

By: /s/ Stephen J. Cosgrove  
Stephen J. Cosgrove  
Chief Accounting Officer